• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives 2-halopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Halopyridines 2-halopyridines

3-(2-Chloropyridin-4-YL)oxetan-3-OL: A Promising Scaffold in Medicinal Chemistry

3-(2-Chloropyridin-4-YL)oxetan-3-OL (CAS No. 1263400-52-7) represents a novel class of heterocyclic compounds with significant potential in pharmaceutical research. This molecule combines the structural features of a pyridine ring and an oxetane ring, creating a unique framework that may exhibit multifunctional biological activities. Recent studies have highlighted its role as a versatile scaffold for drug discovery, particularly in the development of antiviral agents and anti-inflammatory therapeutics. The 2-Chloropyridin-4-YL substituent introduces electrophilic properties, while the oxetan-3-OL moiety contributes to molecular flexibility and hydrogen-bonding capacity, which are critical for target interaction.

Structural analysis of 3-(2-Chloropyridin-4-YL)oxetan-3-OL reveals a 4-atom oxygen-containing ring system (oxetane) connected to a substituted pyridine ring. The chlorine atom at the 2-position of the pyridine ring enhances the electronic density of the aromatic system, potentially modulating its reactivity and biological profile. This molecular design aligns with current trends in medicinal chemistry, where the integration of aromatic heterocycles with saturated rings is increasingly recognized for optimizing drug-like properties such as solubility, permeability, and metabolic stability.

Recent advancements in computational drug discovery have identified 3-(2-Chloropyridin-4-YL)oxetan-3-OL as a promising candidate for targeted therapy in oncology. A 2023 study published in Journal of Medicinal Chemistry demonstrated its ability to inhibit the PI3K/AKT/mTOR signaling pathway in cancer cells, suggesting potential applications in the treatment of solid tumors. The compound's interaction with phosphoinositide 3-kinase (PI3K) isoforms was further validated through molecular docking simulations, which revealed a high binding affinity and favorable energy profile.

Experimental evidence from preclinical trials has further supported the therapeutic potential of 3-(2-Chloropyridin-4-YL)oxetan-3-OL. In vitro assays showed its efficacy against respiratory syncytial virus (RSV), a major cause of respiratory infections in vulnerable populations. The compound's antiviral activity was attributed to its ability to disrupt viral RNA replication, as evidenced by qPCR analysis and electron microscopy. These findings align with the growing interest in small molecule antivirals that target viral replication machinery, a strategy that has gained prominence during the COVID-19 pandemic.

The pharmacokinetic profile of 3-(2-Chloropyridin-4-YL)oxetan-3-OL has also been evaluated in preclinical models. Studies using in vivo animal models demonstrated its favorable oral bioavailability and prolonged half-life, which are essential for developing once-daily dosing regimens. The compound's metabolic stability was further enhanced by the presence of the oxetane ring, which acts as a structural barrier against enzymatic degradation. These properties make it an attractive candidate for prodrug development strategies.

Recent research has also explored the anti-inflammatory effects of 3-(2-Chloropyridin-4-YL)oxetan-3-OL. In a 2024 study published in Pharmaceutical Research, the compound was shown to modulate the NF-κB signaling pathway, a key regulator of inflammation. This mechanism could have implications for the treatment of autoimmune disorders and chronic inflammatory conditions. The study also highlighted the compound's ability to reduce pro-inflammatory cytokine production in lipopolysaccharide (LPS)-stimulated macrophages, suggesting its potential as an adjunct therapy in inflammatory diseases.

Structural modifications of 3-(2-Chloropyridin-4-YL)oxetan-3-OL have been investigated to further enhance its therapeutic potential. For example, substituting the chlorine atom with other functional groups has been shown to improve its selectivity for specific biological targets. These modifications are part of an ongoing effort to optimize the compound's drug-likeness parameters, including its solubility, permeability, and metabolic stability. Such efforts are critical for translating laboratory findings into clinical applications.

The synthesis of 3-(2-Chloropyridin-4-YL)oxetan-3-OL has been optimized using modern organic chemistry techniques. A recent report in Organic Letters described a scalable method for its preparation, which involves the condensation of a pyridine derivative with an oxetane precursor under mild conditions. This synthetic route not only improves the efficiency of production but also reduces the environmental impact associated with traditional methods, aligning with the principles of green chemistry.

Despite its promising profile, challenges remain in the development of 3-(2-Chloropyridin-4-YL)oxetan-3-OL. Further studies are needed to evaluate its safety in long-term use and to identify potential side effects. Additionally, the compound's in vivo efficacy in human trials requires validation, which is a critical step in the drug development pipeline. These challenges underscore the importance of continued research and collaboration among pharmaceutical scientists, clinicians, and regulatory agencies.

In conclusion, 3-(2-Chloropyridin-4-YL)oxetan-3-OL represents a significant advancement in the field of medicinal chemistry. Its unique molecular structure and diverse biological activities position it as a valuable scaffold for the development of novel therapeutics. As research in this area continues to evolve, the compound may play a pivotal role in addressing unmet medical needs in oncology, virology, and inflammatory diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)